Board and Executive Team

Mr Robert Lilley
Chairman - BA (Yale)

40 years experience; SVP, Global Sales & Marketing for Digene Corp from IPO to acquisition by QIAGEN NV (in 2007) creating market & technology leader in molecular Dx. Then, Senior Advisor/Molecular Diagnostics for Developing World at QIAGEN. Consultant to John D Rockefeller 3rd Fund, 23andMe, ImpediMed Pty Ltd, Vertex Pharma, OpGen.


Greg Brown
Non-Executive Director – BAppSc, MBA

35 years experience – medical devices and in-vitro-diagnostics. International roles for Baxter Diagnostics (Australia & UK), Senior Global Marketing Manager for Roche Molecular Systems, and VP Global Strategic Marketing for Digene Corp. Managing Director and CEO for ImpediMed Limited. Boards: StraxCorp, Minomic, UniQuest.


Laurie Hammond
Non-Executive Director – BSc, PhD

35 years experience. Start-up investor and Director. Chairman, Commercialisation Australia. Director inQbator, an early-stage venture fund. Director of, and investor in, several early stage Australian companies in IT and biotech sectors.


Tom Gibbs
Non-Executive Director – BSc, PhD

30 years experience in both start-ups and established companies in Europe and US, including Molecular Devices Corp, Covalys, Med Discovery, Debiopharm. Currently Director at Debiopharm Innovation Fund, Switzerland; responsible for diagnostic investments.


Bea Arnold
Non-Executive Director – MoT, PhD

Bea Arnold

25 years experience in sales, marketing and business development for technology developers and the pharmaceutical industry – BioRad Laboratories, Gnothis SA, Debiopharm Innovation Fund. Currently Associate Director at Debiopharm Innovation Fund, Switzerland;  actively involved in managing and growing diagnostic investment portfolio.